A 32-year-old diabetic male presents with a painful, swollen foot ulcer with green-stained dressing and foul-smelling discharge. Wound culture grows Pseudomonas aeruginosa. Which is the preferred first-line antibiotic regimen for this localized soft tissue infection?

Explanation

## Drug of Choice for Pseudomonas aeruginosa Soft Tissue Infection ### Classification of P. aeruginosa Infections by Severity **Key Point:** The choice of antipseudomonal agent depends on infection severity and site: - **Mild–moderate localized infection** (wound, UTI): fluoroquinolone (ciprofloxacin) monotherapy may suffice. - **Severe systemic infection** (VAP, bacteremia, osteomyelitis, burn wound): dual therapy (β-lactam + aminoglycoside) is mandatory. - **Diabetic foot ulcer with P. aeruginosa**: intermediate severity — β-lactam ± aminoglycoside is preferred over fluoroquinolone monotherapy. ### Why Piperacillin-Tazobactam or Ceftazidime? 1. **Superior bactericidal activity** — β-lactams achieve higher tissue concentrations and faster bacterial kill than fluoroquinolones. 2. **Lower resistance risk** — especially if aminoglycoside is added. 3. **Diabetic foot ulcers are often polymicrobial** — β-lactams cover both gram-negative (P. aeruginosa) and gram-positive (Staphylococcus aureus) organisms better than fluoroquinolones alone. 4. **Biofilm penetration** — P. aeruginosa in chronic wounds forms biofilms; combination therapy is more effective. ### Antipseudomonal Drug Hierarchy for Localized Infection | Severity | First-Line | Alternative | Avoid | |----------|-----------|-------------|-------| | Mild (UTI, wound) | Ciprofloxacin | — | Aminoglycosides (unnecessary) | | Moderate (diabetic foot) | Piperacillin-tazobactam or Ceftazidime ± AG | Ciprofloxacin (if oral step-down) | Monotherapy with cephalosporin alone | | Severe (VAP, bacteremia) | Piperacillin-tazobactam or Ceftazidime + AG | Imipenem + AG | Fluoroquinolone monotherapy | ### Clinical Pearl **High-Yield:** Diabetic foot ulcers with P. aeruginosa often involve: - Mixed aerobic and anaerobic flora. - Biofilm-producing strains (resistant to single agents). - Risk of rapid spread to bone (osteomyelitis). **Therefore:** A broad-spectrum β-lactam (piperacillin-tazobactam covers anaerobes; ceftazidime does not) is preferred. Aminoglycoside may be added if systemic toxicity or osteomyelitis is suspected. ### Why Not the Other Options? **Ciprofloxacin monotherapy (Option A):** Acceptable for mild UTI or uncomplicated wound infection, but suboptimal for diabetic foot ulcer due to: - Risk of resistance emergence in biofilm-producing strains. - Lower bactericidal activity compared to β-lactams. - Inadequate coverage of gram-positive cocci (S. aureus) if polymicrobial. **Imipenem monotherapy (Option C):** While imipenem is an excellent antipseudomonal agent, monotherapy is not preferred for serious infections; combination with aminoglycoside is standard. Also, imipenem is reserved for resistant or complicated cases. **Cefotaxime (Option D):** This 3rd-generation cephalosporin has **poor P. aeruginosa coverage** (unlike ceftazidime) and is not suitable for P. aeruginosa infections. ### Mnemonic **"BETA-Pseudo"** — **B**-lactam (Piperacillin or cephaloporin) + **E**ither **T**azobactam or **A**minoglycoside for **P**seudomonas in moderate-to-severe disease.